|Articles|January 15, 2002
- BioPharm International-01-01-2002
- Volume 15
- Issue 1
Information Age Audits
by Joseph F. Noferi, Daniel E. Worden, and Edward R. Arling Understanding the reach of 21 CFR Part 11 is the first step to assessing its impact. To protect your company, you need integrated quality audit solutions to evaluate the underlying validation of your electronic data.
Advertisement
Articles in this issue
almost 24 years ago
Outsourcing Outlook: E-Sourcing, Internet Facilitates Flexible Collaborationalmost 24 years ago
Inside Washington: Biotechnology in the Limelight, the Year Aheadalmost 24 years ago
Your Vested Interests: The War of the Westalmost 24 years ago
Statistics for Laboratory Method Comparison Studiesalmost 24 years ago
From the Editor: Farewell to 2001 . . . Our Biotech Odyssey Continuesalmost 24 years ago
Liposomes (a Review): Part Two, Drug Delivery SystemsNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
How Enzymatic Platforms May Change the Therapeutic RNA Supply Chain
2
RNAnalytics CPHI Interview, Part Two: Nanoparticle Case Studies and Response to US mRNA Pullback
3
How Is AI Transforming Biomanufacturing and Biopharma Workforce Training?
4
Achieving Real Impact Navigating the Data and Regulatory Barriers to AI Adoption in Bio/pharma
5
